Abbott Laboratories (ABT) has shown some mixed performance in the recent stock market, both underperforming and outperforming competitors on separate occasions. Executive vice president, Lisa Earnhardt and Hubert Allen sold considerable numbers of shares, indicating possible hesitancy. A new diabetes drug has raised investor concerns. However, ABT’s Q1 2024 earnings surpassed expectations and the company has witnessed growth in their nutrition sales. Market downturns haven’t much fazed ABT and the firm continues to gain investor attention. The company's forthcoming Q2 guidance has reportedly overshadowed an earnings beat, sparking interest among investors.
Abbott Laboratories ABT News Analytics from Wed, 11 Oct 2023 07:00:00 GMT to Thu, 09 May 2024 06:09:34 GMT -
Rating +3
- Innovation 0
- Information +2
- Rumor -2
